Biotechnology stocks have been on fire of late. The iShares Biotechnology index is up more than 12 percent over the last month as investors brace for big drug launches, FDA hearings, and greater M&A activity in the coming months. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals, Inc. and Cardium Therapeutics Inc. Access to the full company reports can be found at:
www.paragonreport.com/BPAX
www.paragonreport.com/CXM
J.P. Morgan’s Healthcare Conference in San Francisco this month offered an appealing venue for biotechs to target potential deals in 2012. According to Henry Gosebruch, managing director of health-care mergers and acquisitions at JPMorgan Chase & Co, the analyst firm expects “the large biotechs to be active acquirers in 2012.” Gosebruch added that “investors have rewarded strategic acquisitions that enhance long-term growth and companies that continue their history of developing innovative therapies, as opposed to turning into dividend paying, share-repurchase type low-growth stocks.”
According to a recent report from Bloomberg, biotech companies have historically been less active than their pharmaceutical industry counterparts regarding M&A activity. For example, over the past 4 years, Bristol-Myers has completed an impressive 17 acquisitions, while biotech industry heavyweight, Celgene, has completed a mere 3 acquisitions.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Cardium Therapeutics, Inc. focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs, and definable pathways to partnering, commercialization, and other monetizations. Earlier this month the company announced that it has entered into its first international agreement for the commercialization of Excellagen in the South Korean market. Cardium had recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell its Excellagen professional-use, sterile, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds.
Let us hear your thoughts below.
